FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313532386> ?p ?o ?g. }

• W4313532386 endingPage "233" @default.
• W4313532386 startingPage "233" @default.
• W4313532386 abstract "Importance International guidelines recommend avoiding intravenous thrombolysis (IVT) in patients with ischemic stroke who have a recent intake of a direct oral anticoagulant (DOAC). Objective To determine the risk of symptomatic intracranial hemorrhage (sICH) associated with use of IVT in patients with recent DOAC ingestion. Design, Setting, and Participants This international, multicenter, retrospective cohort study included 64 primary and comprehensive stroke centers across Europe, Asia, Australia, and New Zealand. Consecutive adult patients with ischemic stroke who received IVT (both with and without thrombectomy) were included. Patients whose last known DOAC ingestion was more than 48 hours before stroke onset were excluded. A total of 832 patients with recent DOAC use were compared with 32 375 controls without recent DOAC use. Data were collected from January 2008 to December 2021. Exposures Prior DOAC therapy (confirmed last ingestion within 48 hours prior to IVT) compared with no prior oral anticoagulation. Main Outcomes and Measures The main outcome was sICH within 36 hours after IVT, defined as worsening of at least 4 points on the National Institutes of Health Stroke Scale and attributed to radiologically evident intracranial hemorrhage. Outcomes were compared according to different selection strategies (DOAC-level measurements, DOAC reversal treatment, IVT with neither DOAC-level measurement nor idarucizumab). The association of sICH with DOAC plasma levels and very recent ingestions was explored in sensitivity analyses. Results Of 33 207 included patients, 14 458 (43.5%) were female, and the median (IQR) age was 73 (62-80) years. The median (IQR) National Institutes of Health Stroke Scale score was 9 (5-16). Of the 832 patients taking DOAC, 252 (30.3%) received DOAC reversal before IVT (all idarucizumab), 225 (27.0%) had DOAC-level measurements, and 355 (42.7%) received IVT without measuring DOAC plasma levels or reversal treatment. The unadjusted rate of sICH was 2.5% (95% CI, 1.6-3.8) in patients taking DOACs compared with 4.1% (95% CI, 3.9-4.4) in control patients using no anticoagulants. Recent DOAC ingestion was associated with lower odds of sICH after IVT compared with no anticoagulation (adjusted odds ratio, 0.57; 95% CI, 0.36-0.92). This finding was consistent among the different selection strategies and in sensitivity analyses of patients with detectable plasma levels or very recent ingestion. Conclusions and Relevance In this study, there was insufficient evidence of excess harm associated with off-label IVT in selected patients after ischemic stroke with recent DOAC ingestion." @default.
• W4313532386 created "2023-01-06" @default.
• W4313532386 creator A5000397338 @default.
• W4313532386 creator A5000488846 @default.
• W4313532386 creator A5000627464 @default.
• W4313532386 creator A5001115601 @default.
• W4313532386 creator A5001513593 @default.
• W4313532386 creator A5001804995 @default.
• W4313532386 creator A5002059545 @default.
• W4313532386 creator A5002171223 @default.
• W4313532386 creator A5002472123 @default.
• W4313532386 creator A5002727276 @default.
• W4313532386 creator A5003400904 @default.
• W4313532386 creator A5004010115 @default.
• W4313532386 creator A5004410810 @default.
• W4313532386 creator A5005945990 @default.
• W4313532386 creator A5006104199 @default.
• W4313532386 creator A5006337877 @default.
• W4313532386 creator A5006615877 @default.
• W4313532386 creator A5006654860 @default.
• W4313532386 creator A5007073899 @default.
• W4313532386 creator A5007119825 @default.
• W4313532386 creator A5008573288 @default.
• W4313532386 creator A5010194490 @default.
• W4313532386 creator A5010286822 @default.
• W4313532386 creator A5010477994 @default.
• W4313532386 creator A5010931202 @default.
• W4313532386 creator A5011173721 @default.
• W4313532386 creator A5011652335 @default.
• W4313532386 creator A5012276231 @default.
• W4313532386 creator A5012642756 @default.
• W4313532386 creator A5012995483 @default.
• W4313532386 creator A5013130118 @default.
• W4313532386 creator A5013144930 @default.
• W4313532386 creator A5013227649 @default.
• W4313532386 creator A5013471175 @default.
• W4313532386 creator A5014564210 @default.
• W4313532386 creator A5015147652 @default.
• W4313532386 creator A5015908820 @default.
• W4313532386 creator A5016279456 @default.
• W4313532386 creator A5016607952 @default.
• W4313532386 creator A5017887405 @default.
• W4313532386 creator A5017896219 @default.
• W4313532386 creator A5018605276 @default.
• W4313532386 creator A5018771705 @default.
• W4313532386 creator A5018998576 @default.
• W4313532386 creator A5019141001 @default.
• W4313532386 creator A5019218405 @default.
• W4313532386 creator A5019632697 @default.
• W4313532386 creator A5019802351 @default.
• W4313532386 creator A5020320620 @default.
• W4313532386 creator A5021158956 @default.
• W4313532386 creator A5021549858 @default.
• W4313532386 creator A5022610865 @default.
• W4313532386 creator A5023212844 @default.
• W4313532386 creator A5023593253 @default.
• W4313532386 creator A5024015063 @default.
• W4313532386 creator A5024100883 @default.
• W4313532386 creator A5026092396 @default.
• W4313532386 creator A5027465995 @default.
• W4313532386 creator A5027896811 @default.
• W4313532386 creator A5029061981 @default.
• W4313532386 creator A5029133016 @default.
• W4313532386 creator A5029210202 @default.
• W4313532386 creator A5029667848 @default.
• W4313532386 creator A5029720957 @default.
• W4313532386 creator A5029724926 @default.
• W4313532386 creator A5030015843 @default.
• W4313532386 creator A5030270878 @default.
• W4313532386 creator A5030337320 @default.
• W4313532386 creator A5030835736 @default.
• W4313532386 creator A5032865224 @default.
• W4313532386 creator A5033337810 @default.
• W4313532386 creator A5033929463 @default.
• W4313532386 creator A5033937518 @default.
• W4313532386 creator A5034143823 @default.
• W4313532386 creator A5034245477 @default.
• W4313532386 creator A5034256771 @default.
• W4313532386 creator A5034563349 @default.
• W4313532386 creator A5035186371 @default.
• W4313532386 creator A5035547791 @default.
• W4313532386 creator A5035669748 @default.
• W4313532386 creator A5035717519 @default.
• W4313532386 creator A5037270738 @default.
• W4313532386 creator A5037984400 @default.
• W4313532386 creator A5038293129 @default.
• W4313532386 creator A5038364929 @default.
• W4313532386 creator A5038407720 @default.
• W4313532386 creator A5038711570 @default.
• W4313532386 creator A5039358787 @default.
• W4313532386 creator A5039490283 @default.
• W4313532386 creator A5039977865 @default.
• W4313532386 creator A5040349122 @default.
• W4313532386 creator A5040392881 @default.
• W4313532386 creator A5040723744 @default.
• W4313532386 creator A5041808058 @default.
• W4313532386 creator A5042134711 @default.
• W4313532386 creator A5043035754 @default.

• next